Obinutuzumab for rituximab-dependent nephrotic syndrome
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called obinutuzumab for adults whose nephrotic syndrome (a kidney disease causing swelling and protein in urine) has relapsed after stopping rituximab. It aims to see if obinutuzumab can help prevent future relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of kidney disease called nephrotic syndrome (minimal change disease, focal segmental glomerulosclerosis, or IgM nephropathy) confirmed by a kidney biopsy in the last 5 years.
- You have had a relapse of nephrotic syndrome within 12 months after stopping rituximab (a medication used to prevent relapses).
- Your kidney function (eGFR) is at least 30 mL/min/1.73 m².
- You are willing to use effective contraception during the study and for 18 months after treatment ends (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antibody medicines, obinutuzumab and rituximab, to prevent relapses of steroid-dependent or frequently relapsing nephrotic syndrome in children. It looks at whether one option works better and is safer, including infection risk.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
Hear when a new Nephrotic Syndrome，Idiopathic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.